The latest price target for Rein Therapeutics (NASDAQ:RNTX) was reported by Brookline Capital on January 21, 2026. The analyst firm set a price target for $0.00 expecting RNTX to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Rein Therapeutics (NASDAQ:RNTX) was provided by Brookline Capital, and Rein Therapeutics downgraded their hold rating.

There is no last upgrade for Rein Therapeutics

The last downgrade for Rein Therapeutics Inc happened on January 21, 2026 when Brookline Capital changed their price target from N/A to N/A for Rein Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rein Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rein Therapeutics was filed on January 21, 2026 so you should expect the next rating to be made available sometime around January 21, 2027.

While ratings are subjective and will change, the latest Rein Therapeutics (RNTX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Rein Therapeutics (RNTX) is trading at is $1.17, which is out of the analyst’s predicted range.